<i>In Vivo</i> Efficacy of Tesevatinib in <i>EGFR</i> -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Sani H. Kizilbash(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic)
Cited by 13
Related Papers
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|386
PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel
|Clinical Cancer Research|2008|60